Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy

Journal of Hepatology

Volumn 66, Issue 4, 2017, Pages 862-863

  Klag, Thomas ^a   Dietz, Julia ^b   Werner, Christoph R ^a   Schwarz, Julia M ^a   Lauer, Ulrich M ^a   Beck, Robert ^a   Malek, Nisar P ^a   Sarrazin, Christoph ^b   Berg, Christoph P ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DACLATASVIR; OMBITASVIR; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ALCOHOL ABUSE; ANTIVIRAL THERAPY; CASE REPORT; CHILD PUGH SCORE; DRUG ABUSE; DYSARTHRIA; DYSTONIC DISORDER; HEPATITIS C; HUMAN; LETTER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS GENOME; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; HEPACIVIRUS; RECURRENT DISEASE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; RECURRENCE; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85011024335     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.01.002     Document Type: Letter

References (8)

1. [1] European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 66 (2017), 153–194.
2. [2] AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
3. [3] Simmons, B., Saleem, J., Hill, A., Riley, R.D., Cooke, G.S., Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62 (2016), 683–694.
4. [4] Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T., et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139 (2010), 1593–1601.
5. [5] Hara, K., Rivera, M.M., Koh, C., Demino, M., Page, S., Nagabhyru, P.R., et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?. J Infect Dis 209 (2014), 38–45.
6. [6] Wang, X., Gao, F., Yuan, G., Shi, K., Huang, Y., Chen, Y., et al. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. J Viral Hepat, 2016, 10.1111/jvh.12574.
7. [7] Martinot-Peignoux, M., Stern, C., Maylin, S., Ripault, M.P., Boyer, N., Leclere, L., et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51 (2010), 1122–1126.
8. [8] Lu, Y., Andonov, A., Wong, D.K., Hepatitis C virus late relapse after sustained virologic response from interferon and ribavirin treatment as confirmed by RNA sequencing. J Clin Microbiol 52 (2014), 367–369.